Report Predicts Europe Cell Line Development Market to surpass $2.1 bn by 2024 - Key Players Selexis, Lonza Group, WuXi AppTec, The European Collection of Cell Cultures, Sigma-Aldrich (Merck), GVK BIO and Progenitor Cell Therapy

According to the Graphical Research new growth forecast report titled “Europe Cell Line Development Market analysis based on Product, Source, Cell Line, Application, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 - 2024”, estimated to exceed USD 2.1 billion by 2024.

Key industry players operating in Europe cell line development market are Selexis, Sartorius, Lonza Group, Samsung Biologics, WuXi AppTec, GE Healthcare, Thermo Fisher Scientific, The European Collection of Cell Cultures, Sigma-Aldrich (Merck), GVK BIO, and Progenitor Cell Therapy. Industry players are adopting strategies including merger, acquisition and strategic collaboration and partnership to expand their product portfolio as well as augment consumer base in the industry.

Request for a sample of this research report @ https://www.graphicalresearch.com/request/1066/sample

Growing disease burden across the globe is the key factor that will drive cell line development market growth. Rising demand for vaccines and monoclonal antibodies in treatment of cancer, autoimmune diseases and anti-inflammatory disease will fuel demand for cell line cultures. Developments in biotechnology industry, increasing healthcare expenditure coupled with growing adoption of technologically advanced products should accelerate the cell line development industry growth.

Technological advancements in cell line development products is another major contributor for cell line development business growth. Availability of automated screening methods, enriched medias, disposable equipment and improved expression systems for enhancing cell line development practices will foster market growth. However, stringent regulatory constraints may hamper the cell line development industry growth over the forecast timeframe.

Reagents and media product segment accounted for largest market share of 53.6% in 2017 and is projected to show robust growth throughout the analysis period. Reagents and media form major component of cell culture procedures. Increasing usage of reagents and media in drug discovery, tissue engineering, and other research applications will accelerate the segmental growth over the analysis period.

Mammalian cell cultures segment was valued at USD 650.8 million in 2017 and is estimated to show similar growth during the forecast period. The growth is attributable to increasing adoption of mammalian cell cultures for production of complex biotherapeutic proteins. Mammalian cell cultures are widely used in vaccine production for treatment of mumps, rubella and other diseases. Increasing acceptance of mammalian cell source to produce monoclonal antibodies will further boost the segmental growth.

Recombinant cell line type segment is anticipated to grow at 12.5% CAGR during the forthcoming years. Advent of rDNA technology has drastically increased the demand for recombinant cell lines. Wide adoption of rDNA technology in production of enzymes, synthetic hormones, immunobiologics and other anti-cancer drugs will foster growth of recombinant cell line type segment. Increasing demand for monoclonal antibodies in improving quality of life in patients suffering from cancer, anti-inflammatory disorders and autoimmune diseases will positively impact the segmental growth.

Browse key industry insights from this report Europe Cell Line Development Market in detail along with the table of contents at:
https://www.graphicalresearch.com/industry-insights/1066/europe-cell-line-development-market

Germany cell line development market will grow considerably during the forecast period owing to increasing disease burden in the region. Growing adoption of vaccines and monoclonal antibodies will foster cell line development industry growth. Increasing investments in R&D activities will fuel the demand for cell cultures thereby driving business growth. Developments in biotechnology industry will further augment Germany cell line development market growth.

Segments We Cover:

Europe Cell Line Development Market, by application, 2013-2024 (USD Million)
• Bioproduction market
• Drug discovery
• Toxicity testing
• Tissue engineering
• Research

Europe Cell Line Development Market, by product, 2013-2024 (USD Million)
• Reagents & media
• Equipment
• Accessories & consumables

Europe Cell Line Development Market, by source, 2013-2024 (USD Million)
• Mammalian
• Non-mammalian

Europe Cell Line Development Market, by cell line type, 2013-2024 (USD Million)
• Recombinant cell lines
• Hybridomas
• Continuous cell lines
• Primary cell lines

The above information is provided for the following countries:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Ukraine
• Poland
• Switzerland
• Belgium
• Greece
• Czech Republic
• Netherlands
• Sweden

Make an inquiry for purchasing this report @ https://www.graphicalresearch.com/request/1066/inquiry-before-buying

About Graphical Research:

Graphical Research is a business research firm that provides industry insights, market forecast and strategic inputs through granular research reports and advisory services. We publish targeted research reports with an aim to address varied customer needs, from market penetration and entry strategies to portfolio management and strategic outlook. We understand that business requirements are unique: our syndicate reports are designed to ensure relevance for industry participants across the value chain. We also provide custom reports that are tailored to the exact needs of the customer, with dedicated analyst support across the purchase lifecycle.

Contact Us:

Parikhit B.
Corporate sales,
Graphical Research
Email: sales@graphicalresearh.com
Web: https://www.graphicalresearch.com/

This release was published on openPR.